Lasinavir (INN,[1] previously known as BMS-234475 and CGP-61755) is an experimental peptidomimetic protease inhibitor researched by Novartis and Bristol-Myers Squibb as a treatment for HIV infection.

It was originally discovered by Novartis at Basel (Switzerland).

[2] Its investigation was terminated after Phase I on October 09, 2002.

[3] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.